Sublime

🧬 Biopharma 𝕏 Weekly Recap 📝 Interesting posts/ppl to check out! 👇 🚨 @yaireinhorn Biotech sector shrinks as public biotech companies drop 15% since 2022 📉 » https://t.co/G11bvicBe5 🔬 @GeneInvesting Side-by-side comparison of Casgevy (SCD) vs. Nex Z (ATTR) ⚖️ » https://t.co/COArMTr7ra 💊 @Pharmdca Class effect or same drug mechanism? 🔄 $LLY & $VKTX, $AKRO & $ETNB, $DRUG & $LBPH » https://t.co/oe3sKCf2xV 🧬 @Biotech2k1 RMB39 from $RXRX shows potential in breast & lung cancer 🏥 » https://t.co/1L8Njc4IxO 📊 @KNielsen2000 $NVO P1/2 SC Amycretin data in obesity 🏋️‍♂️ » https://t.co/BG5UhG5Wat 🎯 @BiopharmIQ Ph2 & Ph3 readouts in Q1 2025... 📅 » https://t.co/Qhyf0MizBA 📢 @BioStocks $AKRO reports significant F4 reversal in MASH study ✅ » https://t.co/L0C7E2M5lN 💰 @Andre_AGTC $MDGL/$AKRO relevant – Market expectations on pricing? 💲 » https://t.co/Pwf413WqVI 🔍 @avidresearch $RVMD G12D inhibitor shows strong efficacy & safety 🔬 » https://t.co/0eu0drLjUt 👀 @Biotech2050 Roche Ocrevus plateauing—watch $TGTX Briumvi in 2025 📉 » https://t.co/pnwppii5JV 🧑‍⚕️ @BowTiedBiotech NASH LANDSCAPE 🌍 $ETNB $AKRO $MDGL $VKTX $NVO $LLY $MRK $ALT $IONS $ARWR $GSK $IVA » https://t.co/n0C4aHqGWO 🚑 @doepke_michel 2025: A big year for liver disease in biotech? 🏥 $MDGL $VKTX $AKRO $MREO $KRYS $ARWR $WVE $INBX $ZEAL » https://t.co/zCpND7baLX 📖 @DueDoctor The Baker Brothers’ $4B biotech playbook: 5 key lessons 💼 » https://t.co/1Bh5OYDxkl 💪 @Gantosj $SRPT's GTx strong long-term durability with 5-year NSAA gains 🚀 » https://t.co/TIot6FuMre 🎥 @HOThomasWPhelps Breakdown of how $CRVS #soquelitinib differs from mAb therapies in treating atopic dermatitis 💊 » https://t.co/0ThPtQTG6m ⚡ @JamesEKrause $AXSM FDA approval for SYMBRAVO, eyes next Alzheimer’s decision 🧠 » https://t.co/WiMsUbIxcY 📈 @jfais20 $IOVA: Shorts missing the big picture or bulls overestimating? 🤔 » https://t.co/Jc7oMNCP3s 📊 @learnbiotech Investors should be aware of "p-hacking" strategies used in data analysis ⚠️ » https://t.co/fJgBKvgpow 📉 @paras_biotech Obesity Comp in a single "crowded" graph... 📊 » https://t.co/DytokNu52Y 🏆 @Quantumup1 Stifel reiterated $IOVA Buy-$21-Top Pick 📢 » https://t.co/N9RkezFi2E 💸 @semodough $TGTX: Buyback potential or market mispricing? 🤨 » https://t.co/ECx9xEQXqn 🔬 @shelbynewsad Chaotic biotech ideas: From longevity to extinct species sequencing 🧬 » https://t.co/8lMShwj1VG 📊 @TomSilver39 Cowen: Biotech stock picks for a strong 2025 in uncertain markets 💰 » https://t.co/BZikkuOeKB ... See more

Obesity Comp - in a single graph (from 340 pgs long Obesity report by Stifel) https://t.co/tS4KgA0zZs

Labcorp quietly entered the longevity testing game. Their new Whole Health panel covers 1,000+ biomarkers—similar to what startups like Function & Superpower offer, but DTC. As labs make these moves, the value will shift to interpretation, care, and outcomes. https://t.co/4kEoQoxgst

List of approved Gene Therapies **best selling is ZOLGENSMA w/ 2021 ~$1.4B Revs https://t.co/fsNh706DHv

Biopharma Industry Growth by Drug Modality (2017-2026) https://t.co/pYLtgeAWZs

Curious about salaries in biotech? r/biotech's annual survey data for 2024 is out. With 700+ entries showing a range from $400k - $30k in annual base. Leadership roles earn significantly more and the inflection point is at director level and up. Link below👇 https://t.co/dQs0Np4OlK

3 out of 4 drug approvals come from biotech companies! And half of the projected value of Top 20 pharma drug pipelines also come from "external" innovation, meaning smaller biotech.

Emerging therapeutics for strategic acquirers – What do biopharmas already have and may need? From RBC https://t.co/RXao1AnGT8